EMCDDA. New drugs in Europe, 2012, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2013. 773 kB. #2
Jankovics, P; Váradi, A; Tölgyesi, L; Lohner, S; Németh-Palotás, J; Balla, J. Detection and identification of the new potential synthetic cannabinoids 1-pentyl-3-(2-iodobenzoyl)indole and 1-pentyl-3-(1-adamantoyl)indole in seized bulk powders in Hungary. Forensic Sci. Int., 1 Jan 2012, 214 (1-3), 27-32. 703 kB. https://doi.org/10.1016/j.forsciint.2011.07.011 #3
Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: Origins. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 165-190. 906 kB. https://doi.org/10.1007/164_2018_143 #48
Abbate, V; Schwenk, M; Presley, BC; Uchiyama, N. The ongoing challenge of novel psychoactive drugs of abuse. Part I. Synthetic cannabinoids (IUPAC Technical Report). Pure Appl. Chem., 28 Aug 2018, 90 (8), 1255–1282. 1.0 MB. https://doi.org/10.1515/pac-2017-0605 #3. AM-679
Makriyannis, A; Deng, H. Cannabimimetic indole derivatives
. Patent US 6900236, 31 May 2005. #AM679
Wilkinson, SM; Banister, SD; Kassiou, M. Bioisosteric fluorine in the clandestine design of synthetic cannabinoids. Aust. J. Chem., 10 Feb 2015, 68 (1), 4–8. 451 kB. https://doi.org/10.1071/CH14198 #24